UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Autophagy as a therapeutic target in cancer

Cancer biology & therapy, 2011-01, Vol.11 (2), p.157-168

2011

Volltextzugriff (PDF)

Molecular pathways: autophagy in cancer--a matter of timing and context

Clinical cancer research, 2015-02, Vol.21 (3), p.498-504

2015

Volltextzugriff (PDF)

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Genes & development, 2011-03, Vol.25 (5), p.460-470

2011

Volltextzugriff (PDF)

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Volltextzugriff (PDF)

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Volltextzugriff (PDF)

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

The Lancet (British edition), 2021-07, Vol.398 (10294), p.24-25

2021

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Volltextzugriff (PDF)

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

The New England journal of medicine, 2024-09

2024

Volltextzugriff (PDF)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Volltextzugriff (PDF)

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Volltextzugriff (PDF)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Volltextzugriff (PDF)

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Volltextzugriff (PDF)

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-09-05

2020

Volltextzugriff (PDF)

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-07-PD14-07

2021

Volltextzugriff (PDF)

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-01-GS3-01

2021

Volltextzugriff (PDF)

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-04-PD14-04

2021

Volltextzugriff (PDF)

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3545-3545

2011

Volltextzugriff (PDF)

Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.GS01-05-GS01-05

2024

Volltextzugriff (PDF)

Abstract PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PS14-08-PS14-08

2024

Volltextzugriff (PDF)

Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PS14-05-PS14-05

2024

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaTumors

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Animals
(5)
Oncology
(5)
Autophagy
(4)
Humans
(4)
Mice
(4)
Autophagy - Physiology
(3)
Developmental Biology
(3)
Breast Cancer
(2)
Cancer
(2)
Cell Biology
(2)
Cell Division
(2)
Cell Line
(2)
Cell Survival - Genetics
(2)
Chemotherapy
(2)
Female
(2)
Gene Expression Regulation, Neoplastic
(2)
Genes, Tumor Suppressor
(2)
Genetics & Heredity
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Autophagy as a therapeutic target in cancer

Molecular pathways: autophagy in cancer--a matter of timing and context

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Pembrolizumab for Early Triple-Negative Breast Cancer

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

Abstract PS14-08: Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract PS14-05: Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)

Aktive Filter

Suchergebnisse filtern